MARKET

HROW

HROW

Harrow Health Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.80
+0.49
+5.90%
Opening 12:20 06/22 EDT
OPEN
8.34
PREV CLOSE
8.31
HIGH
8.81
LOW
8.10
VOLUME
106.45K
TURNOVER
--
52 WEEK HIGH
11.24
52 WEEK LOW
4.650
MARKET CAP
233.92M
P/E (TTM)
24.32
1D
5D
1M
3M
1Y
5Y
Insider Trends: Insider Purchase of Harrow Health Stock Extends 90-Day Positive Trend
MT Newswires · 4h ago
Harrow Health Announces Closing of $20 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026
Harrow Health, Inc. (NASDAQ: HROW) ("Harrow Health" or the "Company"), an ophthalmic-focused healthcare company, today announced the closing of its underwritten registered public offering of $20 million aggregate principal amount of 8.625% senior notes due...
GlobeNewswire · 4d ago
Harrow Health prices 8.625% senior notes due 2026
Harrow Health (HROW) has priced its public offering of $17.5M of 8.625% senior notes due 2026.The Notes will be sold at $25.75/Note, for aggregate gross proceeds of ~$18.03M, will be
Seekingalpha · 06/15 06:10
BRIEF-Harrow Health Announces Pricing Of $17.5 Million Aggregate Principal Amount Offering Of 8.625% Senior Notes Due 2026
reuters.com · 06/14 22:21
Harrow Health to raise $17.5M via senior notes offering
Harrow Health (HROW) has commenced an underwritten registered public offering of $17.5M of its 8.625% senior notes due 2026.The Notes will be treated as a single series with the Company’s
Seekingalpha · 06/14 12:02
BRIEF-Harrow Health Announces Offering Of $17.5 Million Of 8.625% Senior Notes Due 2026 And “BB” Rating From Egan-Jones
reuters.com · 06/14 11:46
Harrow Health Announces Offering of $17.5 Million of 8.625% Senior Notes Due 2026 and “BB” Rating from Egan-Jones
NASHVILLE, Tenn., June 14, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced that it has commenced an underwritten registered public offering of $17.5 m...
GlobeNewswire · 06/14 11:45
Harrow Health Launches $17.5 Million Debt Offering
MT Newswires · 06/14 08:21
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HROW. Analyze the recent business situations of Harrow Health Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HROW stock price target is 15.00 with a high estimate of 15.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 117
Institutional Holdings: 15.77M
% Owned: 59.31%
Shares Outstanding: 26.58M
TypeInstitutionsShares
Increased
24
1.04M
New
20
1.94M
Decreased
28
612.18K
Sold Out
6
399.83K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.41%
Pharmaceuticals & Medical Research
-0.40%
Key Executives
Non-Executive Chairman/Independent Director
Robert Kammer
Chief Executive Officer/Director
Mark Baum
Chief Financial Officer/Secretary
Andrew Boll
Corporate Executive
John Saharek
Other
Larry Dillaha
Director
Richard Lindstrom
Other
Dennis Saadeh
Independent Director
Teresa Sparks
Independent Director
R. Lawrence Van Horn
No Data
  • All
  • Financials
  • Insiders
More
About HROW
Harrow Health, Inc owns a portfolio of healthcare and ophthalmology pharmaceutical business, including ImprimisRx, an ophthalmology outsourcing facility and pharmaceutical compounding business. The Company holds interest in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals. The Company also owns royalty rights in four clinical stage drug candidates, which is being developed by Surface Ophthalmics and Melt Pharmaceuticals.

Webull offers kinds of Harrow Health Inc stock information, including NASDAQ:HROW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HROW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HROW stock methods without spending real money on the virtual paper trading platform.